About My Health Careers Internship MedBlogs Contact us

Scientists Identify the Existence of Precursor Cells in Early Prostate Cancers

by Bidita Debnath on September 26, 2013 at 11:33 PM
Font : A-A+

 Scientists Identify the Existence of Precursor Cells in Early Prostate Cancers

At the University of California, San Diego, a team of cancer researchers has identified the existence of precursor cells in early prostate cancers.

These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.


The scientists'' findings, suggesting that potentially lethal castration-resistant prostate carcinoma cells already exist in some cancer patients at the very early stages of their disease, will be published by PLOS ONE on September 25, 2013.

The work describes the isolation and propagation of the earliest prostate cancer cells yet identified in human prostate cancer biopsy samples, allowing the detailed molecular characterization of these very early-stage cancer cells, including analysis of gene expression and mutations.

"Full molecular characterization of the earliest prostate cancer cells will facilitate identification of pharmacological approaches which are not currently available," said Martin Haas, PhD, professor of biology and oncology at UC San Diego Moores Cancer Center. "Development of such early-stage treatments could reduce the incidence of cancer progression to recurrent invasive or metastatic disease."

Treatments for prostate cancer often target androgen pathways. Androgens are male hormones, such as testosterone, that research shows can feed prostate tumors. Castration-resistant (CR) prostate cancer is prostate cancer that has become resistant to medical or surgical treatments that lower testosterone.

The UC San Diego researchers, including Stephen M. Baird, MD, and Daniel J. Donoghue, PhD, isolated a class of prostate cancer cells from early-stage human prostate carcinomas that had been removed by surgical prostatectomy and cultured the cells in a synthetic medium devoid of steroid hormones. In this way, early prostate cancer cells (CR-PrCA) were isolated from dozens of early Stage I prostate carcinoma cases.

When transplanted into the anterior prostates of male SCID mice the cultured cells generated locally invasive human prostate cancers. In castrated mice, in the absence of androgen, the cells grew locally as non-differentiated human cancer cells.

Extensive characterization of these CR-PrCa cells has shown them to share characteristics with multipotent cancer stem or progenitor cells that possess basal prostate cell characteristics.

"One interpretation of our data suggests that the culture-isolated CR-PrCa cells are precursors which, after additional progression steps, would lead to recurrent invasive or metastatic disease," said Haas. "In fact, the cancers that were generated by transplantation into intact SCID mice of the cultured human CR-PrCa cells were pathologically indistinguishable from the original cancer tissue from patients used to grow the cells in culture," he explained.

The hope is that possible future treatments targeting these early-stage prostate cancer precursor cells might increase cures and improve long-term survival rates.

According to the American Urological Association, prostate cancer is the most commonly diagnosed solid organ malignancy in the United States and remains the second leading cause of cancer deaths among American men. Approximately 240,000 new diagnoses of prostate cancer and over 28,000 deaths were estimated in the U.S. in 2012.

Additional contributors to the study include Rita R. FiƱones, PhD, Jo Yeargin, Melissa Lee, Aman Preet Kaur, Clari Cheng, Paulina Sun, Christopher Wu, Catherine Nguyen, Jessica Wang-Rodriguez, MD and April N. Meyer, all of UC San Diego.

The study was funded by the UC San Diego Foundation.

Source: Newswise

News A-Z
News Category
What's New on Medindia
Breast Cancer Awareness Month 2021 - It's time to RISE
First-Ever Successful Pig-To-Human Kidney Transplantation
World Osteoporosis Day 2021 -
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Parkinsons Disease Surgical Treatment Trans-Urethral Resection of the Prostate Cancer Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Medical Management of Prostate Cancer 

Recommended Reading
Prostate Specific Antigen [PSA]
PSA blood test is specific to prostate gland but not necessarily a cancer specific test but is ......
Prostate Cancer Screening
PSA (Prostate Specific Antigen) test and Digital Rectal Examination are two tests that allow ......
Prostate Cancer: Treatment Options
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, ......
Medical Management of Prostate Cancer
Prostate cancer is the second most common cancer in men after skin cancer and it is the sixth leadin...
Prostate Cancer
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can h...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use